China Biologic Products Inc. (NASDAQ:CBPO)’s share price traded up 3.6% during trading on Wednesday . The company traded as high as $112.35 and last traded at $112.05, with a volume of 109,237 shares traded. The stock had previously closed at $108.15.

A number of equities analysts have recently commented on the company. Zacks Investment Research raised China Biologic Products from a “sell” rating to a “hold” rating in a report on Thursday, April 14th. Jefferies Group reissued a “buy” rating on shares of China Biologic Products in a report on Saturday, June 4th. Finally, Credit Suisse Group AG raised China Biologic Products from a “neutral” rating to an “outperform” rating in a report on Tuesday. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $139.20.

The company has a market cap of $3.07 billion and a PE ratio of 34.48. The company’s 50 day moving average price is $111.45 and its 200-day moving average price is $117.83.

China Biologic Products (NASDAQ:CBPO) last posted its quarterly earnings results on Wednesday, May 4th. The biopharmaceutical company reported $0.94 EPS for the quarter, topping the Zacks’ consensus estimate of $0.88 by $0.06. The company earned $85.60 million during the quarter, compared to the consensus estimate of $74 million. The firm’s quarterly revenue was up 21.6% compared to the same quarter last year. Equities research analysts expect that China Biologic Products Inc. will post $4.29 earnings per share for the current fiscal year.

In related news, VP Ming Yin sold 19,618 shares of China Biologic Products stock in a transaction on Friday, May 20th. The stock was sold at an average price of $113.64, for a total transaction of $2,229,389.52. Following the completion of the sale, the vice president now owns 51,419 shares of the company’s stock, valued at $5,843,255.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Wp X. Biologics Llc sold 2,775,000 shares of China Biologic Products stock in a transaction on Wednesday, June 8th. The shares were sold at an average price of $111.00, for a total value of $308,025,000.00. The disclosure for this sale can be found here.

A number of large investors have bought and sold shares of the stock. Calamos Advisors LLC raised its stake in China Biologic Products by 0.6% in the fourth quarter. Calamos Advisors LLC now owns 43,630 shares of the biopharmaceutical company’s stock valued at $6,216,000 after buying an additional 270 shares in the last quarter. Russell Frank Co raised its stake in China Biologic Products by 69.1% in the fourth quarter. Russell Frank Co now owns 14,104 shares of the biopharmaceutical company’s stock valued at $1,993,000 after buying an additional 5,764 shares in the last quarter. CI Investments Inc. raised its stake in China Biologic Products by 22.7% in the fourth quarter. CI Investments Inc. now owns 55,600 shares of the biopharmaceutical company’s stock valued at $7,921,000 after buying an additional 10,300 shares in the last quarter. WCM Investment Management CA raised its stake in China Biologic Products by 22.8% in the fourth quarter. WCM Investment Management CA now owns 60,753 shares of the biopharmaceutical company’s stock valued at $8,655,000 after buying an additional 11,282 shares in the last quarter. Finally, ProShare Advisors LLC purchased a new stake in China Biologic Products during the fourth quarter worth $3,040,000.

China Biologic Products, Inc (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates in the manufacture and sales of human plasma products segment. It has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across over nine categories.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.